Rethinking cryopreservation for safer cell therapies

Live from the Phacilitate.TV studio, this session highlights the importance of selecting the right cryopreservation solution from day one. We will explore how next-generation cryopreservation can improve post-thaw viability while reducing DMSO-related toxicity — a key factor in minimizing patient risk across T cells, HSCs, hMSCs, organoids, and production cell lines.

The session will compare standard 10% DMSO workflows with PentaHibe® Base and PentaHibe® Complete, review published evidence showing how lowering DMSO reduces infusion reactions, and share practical protocol guidance. Featuring Kate Kahr, Pharmacosmos, in conversation with Jeffrey Martin, Flyte.bio.

Key takeaways:
• Cryopreservation choice directly influences patient safety and therapeutic success
• DMSO toxicity is real, and minimizing exposure is a patient safety priority
• Pentahibe delivers high recovery and functionality with DMSO-free and low-DMSO options
• Optimized freeze and thaw protocols are essential, no one size fits all
• Start with quality materials, cGMP supply enables smoother, cost-efficient scale up
• Backed by data, partnerships and toxicology reporting for regulatory confidence